Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
Portfolio Pulse from
Moderna's stock dropped 18% after the company reduced its 2025 sales forecast by $1 billion, now expecting revenue between $1.5 billion and $2.5 billion, primarily in the latter half of the year.
January 13, 2025 | 1:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna's stock fell 18% following a reduction in its 2025 sales forecast by $1 billion, with expected revenue now between $1.5 billion and $2.5 billion.
The significant drop in Moderna's stock price is directly linked to the company's announcement of a $1 billion reduction in its 2025 sales forecast. This indicates potential challenges in revenue generation, affecting investor confidence.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100